Logotype for Riverstone Holdings Limited

Riverstone (AP4) Q1 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Riverstone Holdings Limited

Q1 2025 earnings summary

11 Sep, 2026

Executive summary

  • Revenue for 1Q FY2025 increased by 1.1% year-over-year to RM252.3 million, driven by higher healthcare glove volumes and stable cleanroom demand, but gross profit declined by 15.7% due to higher cost of sales, resulting in a lower gross margin of 32.6% compared to 39.1% in 1Q2024.

  • Net profit for 1Q FY2025 was RM56.4 million, down 21.8% year-over-year, impacted by higher raw material costs, FX losses, and a shift to generic healthcare gloves.

  • Interim dividend of 3.0 sen per share declared for 1Q FY2025, down from 4.0 sen in 1Q2024, representing a 78.7% payout ratio and a 4.0% annualized yield.

  • Riverstone Holdings Ltd specializes in high-tech cleanroom gloves, premium healthcare gloves, and cleanroom consumables, serving electronics, semiconductor, and healthcare sectors.

  • Operates manufacturing and sales sites in Malaysia, China, Thailand, and the Philippines, with a diversified group structure.

Financial highlights

  • Cost of sales rose 11.9% to RM170.1 million, outpacing revenue growth, while gross profit for 1Q FY2025 was RM82.2 million, a 15.7% decrease year-over-year.

  • Net profit for 1Q FY2025 was RM56.4 million, down 21.8% year-over-year and 19.4% sequentially.

  • Operating cash flow for 1Q FY2025 was RM56.0 million; cash and cash equivalents increased to RM759.6 million as of 31 March 2025.

  • Other income decreased by 23.9% to RM5.9 million, mainly due to lower interest income.

  • Diluted EPS was 3.81 sen, down 21.8% year-over-year.

Outlook and guidance

  • The business faces ongoing challenges from price competition, currency fluctuations, volatile raw material prices, and increased production costs.

  • Management is monitoring the potential impact of US tariffs and exploring risk mitigation strategies.

  • Cautiously optimistic on healthcare volume growth and resilient cleanroom demand, with three new healthcare production lines to be commissioned in 2HFY25.

  • Focus remains on transitioning to higher-value specialty solutions and ESG improvements.

  • Targets further reductions in water and electricity usage, waste, and emissions through ongoing and future projects.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more